Katz, Lior <br/><br/>
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.  [electronic resource] 

 -  Inflammatory bowel diseases  Nov 2012 
 - 2026-33 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1536-4844 
<br/><br/><label>Standard No.: </label>10.1002/ibd.22902  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antibodies, Monoclonal--therapeutic use<br/>Crohn Disease--drug therapy<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Gastrointestinal Agents--therapeutic use<br/>Humans<br/>Infliximab<br/>Infusions, Intravenous<br/>Male<br/>Remission Induction<br/>Retrospective Studies<br/>Time Factors<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors<br/>Young Adult